IBRX Stock Analysis Today
Updated Nov 7, 2026 · trends, key levels, insider activity and news
Is IBRX bullish or bearish today?
Daily trend: Uptrend (confirmed) — turns down below $5.54
SEPT signal: Distribution · Strong Bearish
Research grade: A · fair value $14.50 (+69.0%)
IBRX trend by timeframe
| Daily | Uptrend (confirmed) |
|---|---|
| 4 hour | Bullish |
| 1 hour | Strong Bullish |
| 15 min | Strong Bullish |
| 5 min | Strong Bullish |
Trends are calculated from price structure and update during market hours.
IBRX support and resistance levels
Resistance (above)
$8.9514 touches
$10.503 touches
$12.431 touches
Support (below)
$7.9311 touches
$6.705 touches
$5.933 touches
Upside zones: $10.46 / $11.11 / $11.76
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 330-day net
—Hedge fund holders
324Latest IBRX news and filings
- ProductFiscal.ai
ImmunityBio says first European patients treated with ANKTIVA
ImmunityBio reported that the first patients in Europe have received treatment with ANKTIVA. The company did not give further details in the headline.
- ProductBenzinga
ImmunityBio treats first European patient with ANKTIVA plus BCG
ImmunityBio said the first patient in Europe received ANKTIVA combined with Bacillus Calmette-Guérin. This marks an early use of the treatment in a European patient.
- ProductFiscal.ai
ImmunityBio's CD19 CAR-NK therapy shows encouraging results in early trial
The company said its CD19 CAR-NK treatment produced encouraging findings in a study conducted at an early phase. The results cover the initial stage of testing.
- ProductFiscal.ai
ImmunityBio locks database for ANKTIVA plus BCG registrational trial
ImmunityBio said it has locked the database for a registrational study of ANKTIVA combined with BCG. A database lock typically precedes the analysis of trial results.
- GuidanceBenzinga
ImmunityBio Expects November 2026 Topline Data, Q4 2026 sBLA Filing for ANKTIVA Plus BCG
ImmunityBio said it still plans to report topline results in November 2026 and to submit an sBLA to the FDA in the fourth quarter of 2026 for ANKTIVA combined with BCG in BCG-naïve NMIBC patients.
- ProductBenzinga
ImmunityBio reports long-term success in bladder cancer study
ImmunityBio said a study of its bladder cancer treatment showed long-term success. The company did not disclose additional details in the headline.
- AnalystBenzinga
Jefferies keeps Buy rating on ImmunityBio, lifts target to $14
Jefferies reiterated its Buy rating on ImmunityBio and raised its price target to $14. The update reflects the analyst's revised expectations for the company.
Live IBRX chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Is IBRX bullish or bearish today?
IBRX daily trend: Uptrend (confirmed) — turns down below $5.54. SEPT signal: Distribution (Strong Bearish). Updated Nov 7, 2026.
What is IBRX's trend on each timeframe?
Daily: Uptrend (confirmed); 4 hour: Bullish; 1 hour: Strong Bullish; 15 min: Strong Bullish; 5 min: Strong Bullish.
What are IBRX support and resistance levels?
Support: $7.93, $6.70, $5.93. Resistance: $8.95, $10.50, $12.43. Last price $8.63.
Are insiders buying or selling IBRX?
Insider signal: Sell. Last 30 days: 0 buys, 3 sells. 324 hedge funds hold IBRX.
What is the latest news on IBRX?
Nov 4, 2026: ImmunityBio says first European patients treated with ANKTIVA · Nov 4, 2026: ImmunityBio treats first European patient with ANKTIVA plus BCG · Oct 31, 2026: ImmunityBio's CD19 CAR-NK therapy shows encouraging results in early trial